About Us
T cell immunotherapy
Creating new paths in patient care
TCUBEit Inc. aims to revolutionize immunotherapy by delivering effective T cell therapies that are not only powerful but also accessible to more patients.
Through groundbreaking technology, we are developing next-generation T cell treatments that achieve higher survival rates, improved persistence, and precise targeting against cancer.
Pioneering a new era of T cell therapies, TCUBEit Inc. offers an innovative platform technology that provides safe, simple, and cost-effective treatments designed to strengthen the immune system’s ability to fight cancer and other diseases.
Employees
15 people
(5 PhD, 5 Masters, 5B.S. …)
Establishment
October 18, 2019
Main Business
- Next-gen T cell Manufacturing Platform
T-CAMP, T-GUNS - Pipelines for HCC and gastric cancer
- Human Immunity Profiling
Our Commitment
Safe
Our therapies are designed with patient safety in mind, utilizing
non-viral, mRNA-based
technology to minimize risks.
Simple
We streamline the process,
making T cell therapy easier to administer with minimal complexity.
Investment Highlight
T-CAMP
- T-CAMP: MC-EXP+ T-CAST
(Optimize T-cell culture utilizing AI) - T-CAMP7, T-CAMP5: cell culture period of 5 – 7 days
- Expand therapeutic T cells with improved
bio-persistence
T-GUNS
- Novel single variable domain TCR structure
- Engineered transmembrane domain
to escape mispairing with endogeneous TCRs - mRNA platforms to increase convenience/safety
Differentiation strategies
- Independent underlying technology reduces safety/development ease/cost
- Securing unexplored areas
using mRNA platform - Production/Proof using own GMP Compatible Cleanroom
Business investment
- Pre-A investment completed
: CK, IMM, KIP, Bokwang, Hanlim - Unicorn-company certified by
Korean government - Expansion through joint basic research
l 3 cases in progress
Expansion / Partnerships
- Expansion through joint basic research
3 cases in progress - Synergy through co-administration of immuno-cancer drugs | ICI
- Expandability and flexibility of production processes l International Collaboration